StarZero All shows Try the podcast clipper →

Aug 12, 2019 · 24m · top-founders

1479 Are they actually better than WebMD w $500k+ in Revenue?

Tal Givoly · 11m spoken Nathan Latka · 9m spoken
0:00 / 0:00

gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions

In this episode of The Top Entrepreneurs Podcast, host Nathan Latka interviews Medivisor co-founder and CEO Tal Givoly to analyze the health-tech startup's personalized medical information platform, dual monetization model, and enterprise growth metrics. Givoly breaks down Medivisor's patent-backed software architecture, biopharmaceutical contract values, fundraising efforts, and path toward reaching profitability with over 130,000 subscribers.

How this conversation actually went

Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Nathan holds 42.4% of the talking time here. How this is scored →

Nathan as informed peer 5.2 Guest teaching 3.2 Guest disagreement 3.7 Nathan pushing back 4.8
05100:0010:0020:000:00–5:56 · Nathan as informed peer 4/10 Book Promotion: How to Be a Capitalist Without Any Capital Following an extended solo promo, Nathan probes how Medivisor differentiates from WebMD and overcomes onboarding friction. Tal explains their personalized medical questionnaires and biopharma licensing model.5:56–8:58 · Nathan as informed peer 3/10 Medivisor's Origins and Personal Motivation for Founding Tal details his personal motivation for founding Medivisor, the academic backgrounds of his co-founders, and their global network of contributors. Nathan asks whether their patent has been legally defended.9:01–11:41 · Nathan as informed peer 4/10 Fundraising History, Subscriber Scale, and Path to Profitability Nathan digs into Medivisor's fundraising history and path to profitability. Tal outlines plans to raise a few million dollars and achieve breakeven within 12 months.11:44–15:18 · Nathan as informed peer 5/10 Sponsor Advertisement: Pantheon WebOps Platform After an ad read, Nathan presses Tal to nail down historical ACV figures and deal counts for biopharma contracts. Tal initially hedges before conceding an 80k-90k range and closing fewer than 10 total deals.15:21–21:20 · Nathan as informed peer 7/10 Content Licensing Model, Product Delivery, and Customization Debates Nathan challenges Tal on whether Medivisor is a scalable software platform or a customized professional services agency. Tal pushes back vigorously, explaining that a minor API tweak on a six-figure contract does not make it a custom consulting shop.21:22–24:22 · Nathan as informed peer 8/10 Upfront Cash Flow Strategy vs Venture Dilution Nathan advocates collecting multi-year cash upfront to avoid equity dilution, then calculates Medivisor's implied 600k-700k revenue run rate from Tal's prior metrics. Tal resists confirming the figures and exits the call.0:00–5:56 · Guest teaching 4/10 Book Promotion: How to Be a Capitalist Without Any Capital Following an extended solo promo, Nathan probes how Medivisor differentiates from WebMD and overcomes onboarding friction. Tal explains their personalized medical questionnaires and biopharma licensing model.5:56–8:58 · Guest teaching 3/10 Medivisor's Origins and Personal Motivation for Founding Tal details his personal motivation for founding Medivisor, the academic backgrounds of his co-founders, and their global network of contributors. Nathan asks whether their patent has been legally defended.9:01–11:41 · Guest teaching 2/10 Fundraising History, Subscriber Scale, and Path to Profitability Nathan digs into Medivisor's fundraising history and path to profitability. Tal outlines plans to raise a few million dollars and achieve breakeven within 12 months.11:44–15:18 · Guest teaching 2/10 Sponsor Advertisement: Pantheon WebOps Platform After an ad read, Nathan presses Tal to nail down historical ACV figures and deal counts for biopharma contracts. Tal initially hedges before conceding an 80k-90k range and closing fewer than 10 total deals.15:21–21:20 · Guest teaching 6/10 Content Licensing Model, Product Delivery, and Customization Debates Nathan challenges Tal on whether Medivisor is a scalable software platform or a customized professional services agency. Tal pushes back vigorously, explaining that a minor API tweak on a six-figure contract does not make it a custom consulting shop.21:22–24:22 · Guest teaching 2/10 Upfront Cash Flow Strategy vs Venture Dilution Nathan advocates collecting multi-year cash upfront to avoid equity dilution, then calculates Medivisor's implied 600k-700k revenue run rate from Tal's prior metrics. Tal resists confirming the figures and exits the call.0:00–5:56 · Guest disagreement 2/10 Book Promotion: How to Be a Capitalist Without Any Capital Following an extended solo promo, Nathan probes how Medivisor differentiates from WebMD and overcomes onboarding friction. Tal explains their personalized medical questionnaires and biopharma licensing model.5:56–8:58 · Guest disagreement 2/10 Medivisor's Origins and Personal Motivation for Founding Tal details his personal motivation for founding Medivisor, the academic backgrounds of his co-founders, and their global network of contributors. Nathan asks whether their patent has been legally defended.9:01–11:41 · Guest disagreement 2/10 Fundraising History, Subscriber Scale, and Path to Profitability Nathan digs into Medivisor's fundraising history and path to profitability. Tal outlines plans to raise a few million dollars and achieve breakeven within 12 months.11:44–15:18 · Guest disagreement 3/10 Sponsor Advertisement: Pantheon WebOps Platform After an ad read, Nathan presses Tal to nail down historical ACV figures and deal counts for biopharma contracts. Tal initially hedges before conceding an 80k-90k range and closing fewer than 10 total deals.15:21–21:20 · Guest disagreement 7/10 Content Licensing Model, Product Delivery, and Customization Debates Nathan challenges Tal on whether Medivisor is a scalable software platform or a customized professional services agency. Tal pushes back vigorously, explaining that a minor API tweak on a six-figure contract does not make it a custom consulting shop.21:22–24:22 · Guest disagreement 6/10 Upfront Cash Flow Strategy vs Venture Dilution Nathan advocates collecting multi-year cash upfront to avoid equity dilution, then calculates Medivisor's implied 600k-700k revenue run rate from Tal's prior metrics. Tal resists confirming the figures and exits the call.0:00–5:56 · Nathan pushing back 3/10 Book Promotion: How to Be a Capitalist Without Any Capital Following an extended solo promo, Nathan probes how Medivisor differentiates from WebMD and overcomes onboarding friction. Tal explains their personalized medical questionnaires and biopharma licensing model.5:56–8:58 · Nathan pushing back 2/10 Medivisor's Origins and Personal Motivation for Founding Tal details his personal motivation for founding Medivisor, the academic backgrounds of his co-founders, and their global network of contributors. Nathan asks whether their patent has been legally defended.9:01–11:41 · Nathan pushing back 3/10 Fundraising History, Subscriber Scale, and Path to Profitability Nathan digs into Medivisor's fundraising history and path to profitability. Tal outlines plans to raise a few million dollars and achieve breakeven within 12 months.11:44–15:18 · Nathan pushing back 6/10 Sponsor Advertisement: Pantheon WebOps Platform After an ad read, Nathan presses Tal to nail down historical ACV figures and deal counts for biopharma contracts. Tal initially hedges before conceding an 80k-90k range and closing fewer than 10 total deals.15:21–21:20 · Nathan pushing back 8/10 Content Licensing Model, Product Delivery, and Customization Debates Nathan challenges Tal on whether Medivisor is a scalable software platform or a customized professional services agency. Tal pushes back vigorously, explaining that a minor API tweak on a six-figure contract does not make it a custom consulting shop.21:22–24:22 · Nathan pushing back 7/10 Upfront Cash Flow Strategy vs Venture Dilution Nathan advocates collecting multi-year cash upfront to avoid equity dilution, then calculates Medivisor's implied 600k-700k revenue run rate from Tal's prior metrics. Tal resists confirming the figures and exits the call.

speaking balance: gold is Nathan, purple is the guest (3 minute bins)

0:00 · Nathan 73.6% · guest 26.4%0:00 · Nathan 73.6% · guest 26.4%3:00 · Nathan 24.5% · guest 75.5%3:00 · Nathan 24.5% · guest 75.5%6:00 · Nathan 15.3% · guest 84.7%6:00 · Nathan 15.3% · guest 84.7%9:00 · Nathan 43.6% · guest 56.4%9:00 · Nathan 43.6% · guest 56.4%12:00 · Nathan 58.5% · guest 41.5%12:00 · Nathan 58.5% · guest 41.5%15:00 · Nathan 39.8% · guest 60.2%15:00 · Nathan 39.8% · guest 60.2%18:00 · Nathan 23.8% · guest 76.2%18:00 · Nathan 23.8% · guest 76.2%21:00 · Nathan 52.4% · guest 47.6%21:00 · Nathan 52.4% · guest 47.6%24:00 · Nathan 93.3% · guest 6.7%24:00 · Nathan 93.3% · guest 6.7%
Sharpest disagreement ▶ 20:10 Tal rejects Nathan's binary classification

Tal firmly pushes back against Nathan's claim that a business must be either purely uniform SaaS or heavy professional services, using the ratio of 2k in integration work on a 200k deal to prove his point.

 Hardest push from Nathan ▶ 20:00 Nathan calls out product customization contradiction

Nathan aggressively refuses Tal's mixed framing, asserting that one cannot claim deals are completely non-uniform without being a custom services business.

 Biggest teaching moment ▶ 20:20 Tal explains low-overhead API integration economics

Tal educates Nathan on how modern API integrations allow standard platform delivery while accommodating minor bespoke partner requirements without shifting into agency services.

 Nathan holds their own ▶ 22:55 Nathan models Medivisor's revenue from stated deal metrics

Nathan demonstrates sharp financial acumen by instantly multiplying Tal's stated biopharma deal count, ACV, and revenue split to back into an estimated 600k-700k annual run rate.
the scores for every segment, with the reasoning behind each
ChapterTopicNathan as informed peerGuest teachingGuest disagreementNathan pushing backWhy
Book Promotion: How to Be a Capitalist Without Any Capital 4423 Following an extended solo promo, Nathan probes how Medivisor differentiates from WebMD and overcomes onboarding friction. Tal explains their personalized medical questionnaires and biopharma licensing model.
Medivisor's Origins and Personal Motivation for Founding 3322 Tal details his personal motivation for founding Medivisor, the academic backgrounds of his co-founders, and their global network of contributors. Nathan asks whether their patent has been legally defended.
Fundraising History, Subscriber Scale, and Path to Profitability 4223 Nathan digs into Medivisor's fundraising history and path to profitability. Tal outlines plans to raise a few million dollars and achieve breakeven within 12 months.
Sponsor Advertisement: Pantheon WebOps Platform 5236 After an ad read, Nathan presses Tal to nail down historical ACV figures and deal counts for biopharma contracts. Tal initially hedges before conceding an 80k-90k range and closing fewer than 10 total deals.
Content Licensing Model, Product Delivery, and Customization Debates 7678 Nathan challenges Tal on whether Medivisor is a scalable software platform or a customized professional services agency. Tal pushes back vigorously, explaining that a minor API tweak on a six-figure contract does not make it a custom consulting shop.
Upfront Cash Flow Strategy vs Venture Dilution 8267 Nathan advocates collecting multi-year cash upfront to avoid equity dilution, then calculates Medivisor's implied 600k-700k revenue run rate from Tal's prior metrics. Tal resists confirming the figures and exits the call.

Statements from this episode (11)

Prediction Not checkable as stated
Givoly: Biopharma will eventually become Medivisor's largest revenue stream
“So, ultimately, over time, it's going to be, ah, basically, ah, the biopharma is gonna be larger.”
Tal Givoly Aug 12, 2019 ▶ 5:44
Disclosure
Givoly: Medivisor revenue is split fifty-fifty between licensing and biopharma
“Today it's about fifty-fifty.”
Tal Givoly Aug 12, 2019 ▶ 5:53
Assertion Contradicted
Givoly: Co-founder Oren Fierst previously founded over 10 health-tech companies
“He started over 10 other health tech companies.”
Tal Givoly Aug 12, 2019 ▶ 7:22
Disclosure
Givoly: Medivisor has a core team of six to seven full-time staff
“No, no, we don't have 35 full-time staff. It's all, most of the team is part-time, there's a core of about six, seven people full-time.”
Tal Givoly Aug 12, 2019 ▶ 7:42
Assertion Not checkable as stated
Givoly: Medivisor has over 130,000 subscribers across 129 countries
“We're, by the way, helping over 130,000 subscribers. In a 129 countries, though the vast majority are in the US.”
Tal Givoly Aug 12, 2019 ▶ 10:00
Disclosure
Givoly: Medivisor's clinical trial acceleration deals are six-figure contracts
“It's usually bigger, longer deals to longer term engagement. So, for example, a clinical trial that wants to be accelerated, it could be a six-figure deal to work with us to help accelerate that trial.”
Tal Givoly Aug 12, 2019 ▶ 11:26
Assertion Not checkable as stated
Givoly: Medivisor's last four biopharma deals closed inbound within three months
“So far, the interesting thing is that the last four deals have come to us and closed within three months. So without us even meeting them. So yeah, we had phone conversations and so on, but the last deals have actually discovered us online found out that we co…”
Tal Givoly Aug 12, 2019 ▶ 13:34
Assertion Not checkable as stated
Givoly: Medivisor has closed approximately ten biopharma deals since launch
“No, no, no. We're close to the 10 than to a hundred.”
Tal Givoly Aug 12, 2019 ▶ 14:55
Disclosure
Givoly: Leukemia & Lymphoma Society licenses Medivisor's content
“The Leukemia Lymphoma Society, they have an online community that they're trying to cultivate. They sponsor blood cancer as a med advisor, and they license the content that we provide so that we could feed it into their community members.”
Tal Givoly Aug 12, 2019 ▶ 15:44
Opinion
Givoly: WebMD's information is static and fails to reflect new research
“WebMD's information is essentially fairly static. There's a page about lymphoma and about treatment options, but it doesn't get updated every research paper that gets updated.”
Tal Givoly Aug 12, 2019 ▶ 16:49
Disclosure
Givoly: Medivisor has signed fewer than ten long-term content licensing deals
“No, less. This is much rarer. So so we have a handful of those, but they're long term, so they're nice.”
Tal Givoly Aug 12, 2019 ▶ 21:26
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 2,600 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more